Browsing Tag
adalimumab
8 posts
Mabwell’s adalimumab biosimilar wins BPOM nod: Is Southeast Asia becoming the next battleground for biosimilars?
Mabwell’s adalimumab biosimilar wins approval in Indonesia. Find out what this means for Southeast Asia’s biologics market and Mabwell’s global ambitions.
Sandoz and Biocon Biologics sign distribution deal for key immunology drug
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd and a prominent player in the global biosimilars market,…
Biocon Biologics wraps up integration of former Viatris biosimilars business
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful integration of the acquired biosimilars…
Biocon Biologics debuts biosimilar HULIO in US market
In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability…
Pfizer, AbbVie settle global IP for Humira biosimilar, paving way for European launch
In a significant step towards expanding biosimilar access, Pfizer and AbbVie have resolved all global intellectual property disputes…
Mylan launches Hulio, a biosimilar to Humira, across major European markets
Mylan has officially launched Hulio, its biosimilar to AbbVie’s Humira (adalimumab), across major European markets. This launch follows…
Boehringer Ingelheim’s Cyltezo achieves clinical equivalence to Humira in Phase 3 psoriasis trial
German pharmaceutical giant Boehringer Ingelheim has announced a significant milestone in the treatment of moderate-to-severe chronic plaque psoriasis.…
Novartis’ Sandoz gains EC approval for biosimilar Hyrimoz across multiple therapeutic areas
In a significant advancement for biopharmaceuticals, Novartis’ division Sandoz has secured approval from the European Commission (EC) for…